Vaccine a promising immunotherapy option for head and neck cancer patients | [Pakistan Journal of Medical Sciences • 2024]

Author(s):

1. Syed Fareed Mohsin: Department of Oral and Maxillofacial Diagnostic Sciences. College of Dentistry, Qassim University, Buraydah, Saudi Arabia.

Abstract:

Head and neck cancer (HNC) is a diversified group of tumors arising from the upper aerodigestive tract, encompassing the oral cavity, larynx, and pharynx. Globally, this particular cancer ranks sixth in prevalence, resulting in an annual mortality rate above 325,000 individuals. Surgery, radiation, and chemotherapy are the primary therapeutic options for HNC, which are frequently used in combination. Despite their extensive use, these treatments are typically unsuccessful and can significantly impair patient quality of life. Therapeutic vaccinations are administered to cancer patients instead of preventative immunizations administered to a healthy population. The eficacy of this modality has considerably transformed the application and success of cancer management by providing an additional and efective therapeutic option for patients. Cancer treatment has been revolutionized by introducing Immune Checkpoint receptors inhibitors (ICR), such as anti-CTLA4, anti-PD-1, and anti-PD-L1.3. ICR have also established immunity against self-generated cancerous cells. Cancer vaccines have shown extraordinary synergistic potential with checkpoint inhibitors to maximize tumor-specific CD8+ expansion and activity, which detects and destroys tumor cells. Personalized neoantigen vaccination therapies can potentially combat the heterogeneity of each patient's tumor. The findings of this review suggest that recent advances in cancer immunology and genetics imply that cancer vaccination can be a promising alternative treatment for head and neck cancer patients. This review conducted a comprehensive literature search to identify relevant studies on immunotherapy options for head and neck cancer patients. The search strategy was designed to capture a wide range of peer-reviewed articles, conference proceedings, and grey literature from 2013 to 2023. The databases searched to ensure comprehensive coverage of the literature included PubMed, Web of Science, and Google Scholar; to include grey literature and articles not indexed in traditional databases.

Page(s): 1578-1583

DOI: 10.12669/pjms.40.7.8791

Published: Journal: Pakistan Journal of Medical Sciences, Volume: 40, Issue: 7, Year: 2024

Keywords:

Immunotherapy , head and neck cancer , Checkpoint receptors , Therapeutic Vaccine , Syed Fareed Mohsin

References:

[1] Sung H,Ferlay J,Siegel RL,Laversanne M,Soerjomataram I,Jemal A,Bray F,Cancer J Clin F .2021 .GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Global Cancer Statistics, 10(3) : 209-249.

[2] Johnson DE,Burtness B,Leemans CR,Lui VWY,Bauman JE,Grandis JR .2020 .Head and neck squamous cell carcinoma. Nat Rev Dis Primers, 10(1) : 92.

[3] Thomas SJ,Penfold CM,Waylen A,Ness AR .2018 .The changing aetiology of head and neck squamous cell cancer: A tale of three cancers? Clin Otolaryngol. , 10(4) : .

[4] Mishra A,Meherotra R,Pac J Cancer Prev R .2014 .Global burden and regional trends in India. , 15(2) : 537-550.

[5] Shaw R,Beasley N.,Otol J Laryngol .2016 .Aetiology and risk factors for head and neck cancer: United Kingdom National Multidisciplinary Guidelines. , 10(S2) : S9-S12.

[6] Vos T,Abajobir AA,Abbafati C,Abbas KM,Abate KH,Abd-Allah F .2017 .A systematic analysis for the Global Burden of Disease Study 2016. , 6736(17) : 32154-2.

[7] Kanwal M,Haider G,Zareef U,Saleem S U .2019 .Addiction of tobacco chewing and smoking in the patients of head and neck squamous cell carcinoma: A descriptive epidemiological study in Pakistan. Pak J Med Sci, 10(6) : 1309-1717.

[8] Syrjänen S,Waterboer T,Kero K,Rautava J,Syrjänen K,Grenman S .2015 .Oral human papillomavirus infection in men might contribute to HPV serology. Europ J Clin Microbiol Infect Dis, 10(2) : 237-245.

[9] Yom SS,Mallen-St. Clair J,Ha PK .2017 .Controversies in Postoperative Irradiation of Oropharyngeal Cancer After Transoral Surgery. Surg Oncol Clin N Am, 01(3) : 357-370.

[10] Bray F,Ferlay J,Soerjomataram I,Siegel RL,Torre LA,Jemal A .2018 .GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 10(6) : 392-424.

[11] Chaturvedi AK,Anderson WF,Lortet-Tieulent J,Paula Curado M,Ferlay J,Franceschi S .2013 .Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol, 50(36) : 4550-4559.

[12] Borst J,Ahrends T,Bąbała N,Melief CJM,Kastenmüller W. .2018 .CD4+T cell help in cancer immunology and immunotherapy. Nat Rev Immunol, 10(10) : 635-647.

[13] Ferris ST,Durai V,Wu R,Theisen DJ,Ward JP,Bern MD .2020 .cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity. Nature, 10(7822) : 624-629.

[14] Ott PA,Hu Z,Keskin DB,Shukla SA,Sun J,Bozym DJ .2017 .An immunogenic personal neoantigen vaccine for patients with melanoma. Nature, 10(7662) : 217-221.

[15] Khan SA,Zia S,Naqvi SU,Adel H,Adil SO,Hussain M. .2017 .Relationship of oral tumor thickness with the rate of lymph node metastasis in neck based on CT scan. Pak J Med Sci, 10(2) : 353-357.

[16] Yarchoan M,Johnson BA,Lutz ER,Laheru DA,Jaffee EM .2016 .Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer, 10(4) : .

[17] Hollingsworth RE,Jansen K. Turning .2019 .4(1):7. NPJ Vaccines, 10 : .

[18] Coulie PG,van der Bruggen P,Boon T. .2014 .Tumour antigens recognized by T lymphocytes: At the core of cancer immunotherapy. Nat Rev Cancer, 10(2) : 135-146.

[19] Yang H,Kim DS .2015 .Peptide immunotherapy in vaccine development: From epitope to adjuvant. Adv Protein Chem Struct Biol, 03 : .

[20] Lopes A,Vandermeulen G,Préat V .2019 .Cancer DNA vaccines: current preclinical and clinical developments and future perspectives. J Exp Clin Cancer Res, 10(1) : 146.

[21] Hu Y,Lu L,Xia Y,Chen X,Chang AE,Hollingsworth RE .2016 .Therapeutic efficacy of cancer stem cell vaccines in the adjuvant setting. Cancer Res, 15(16) : 0008-5472.

[22] Perri F,Ionna F,Longo F,de Angelis C,Ottaiano A .2019 .. Immune Response Against Head and Neck Cancer: Biological Mechanisms and Implication on Therapy. Transl Oncol, 11 : 262-274.

[23] Blanchard P,Baujat B,Holostenco V,Bourredjem A,Baey C,Bourhis J .2011 .Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): A comprehensive analysis by tumour site. Radiother Oncol, 05(1) : 281-293.

[24] Grinshtein N,Bridle B,Wan Y,Bramson JL Y .2009 .Neoadjuvant vaccination provides superior protection against Tumor relapse following surgery compared with adjuvant vaccination. Cancer Res, 08(9) : 0008-5472.

[25] Liu J,Blake SJ,Yong MCR,Harjunpää H,Ngiow SF,Takeda K .2016 .Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov, 16(12) : 2159-8290.

[26] Topalian SL,Taube JM,Pardoll DM .2020 .Neoadjuvant checkpoint blockade for cancer immunotherapy. Science, 10(6477) : .

[27] Schoenfeld JD,Hanna GJ,Jo VY,Rawal B,Chen YH,Catalano PS .2020 .Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 OpenLabel Randomized Clinical Trial. JAMA Oncol, 10(10) : 1563-1570.

[28] Uppaluri R,Campbell KM,Egloff AM,Zolkind P,Skidmore ZL,Nussenbaum B .2020 .Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase-II Trial. Clin Cancer Res, 20(19) : 1078-0432.

[29] Leidner R,Crittenden M,Young K,Xiao H,Wu Y,Couey MA .2021 .Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma. - 002485, 10(5) : .

[30] Price KAR,Nichols AC,Shen CJ,Rammal A,Lang P,Palma DA .2020 .Novel Strategies to Effectively De-escalate Curative-Intent Therapy for Patients With HPV-Associated Oropharyngeal Cancer: Current and Future Directions. Am Soc Clin Oncol Educ Book, 10 : 1-13.

[31] Tan YS,Sansanaphongpricha K,Prince MEP,Sun D,Wolf GT,Lei YL .2018 .Engineering Vaccines to Reprogram Immunity against Head and Neck Cancer. J Dent Res, 10(6) : 627-634.

[32] McArdel SL,Dugast AS,Hoover ME,Bollampalli A,Hong E,Castano Z .2021 .Anti-tumor effects of RTX-240: an engineered red blood cell expressing 4-1BB ligand and interleukin-15. , 10(9) : 2701-2719.

Citations

Downloads

Views